- Home
- MAC vs ICUI Comparison
MAC vs ICUI Comparison
Compare MAC & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- ICUI
- Stock Information
- Founded
- MAC 1964
- ICUI 1984
- Country
- MAC United States
- ICUI United States
- Employees
- MAC N/A
- ICUI N/A
- Industry
- MAC Real Estate Investment Trusts
- ICUI Medical/Dental Instruments
- Sector
- MAC Real Estate
- ICUI Health Care
- Exchange
- MAC Nasdaq
- ICUI Nasdaq
- Market Cap
- MAC 4.1B
- ICUI 3.4B
- IPO Year
- MAC 1994
- ICUI 1992
- Fundamental
- Price
- MAC $16.71
- ICUI $112.85
- Analyst Decision
- MAC Hold
- ICUI Strong Buy
- Analyst Count
- MAC 12
- ICUI 5
- Target Price
- MAC $18.95
- ICUI $195.00
- AVG Volume (30 Days)
- MAC 1.6M
- ICUI 264.6K
- Earning Date
- MAC 08-11-2025
- ICUI 08-07-2025
- Dividend Yield
- MAC 4.07%
- ICUI N/A
- EPS Growth
- MAC N/A
- ICUI N/A
- EPS
- MAC N/A
- ICUI N/A
- Revenue
- MAC $1,012,216,000.00
- ICUI $2,372,504,000.00
- Revenue This Year
- MAC $12.20
- ICUI N/A
- Revenue Next Year
- MAC N/A
- ICUI N/A
- P/E Ratio
- MAC N/A
- ICUI N/A
- Revenue Growth
- MAC 20.66
- ICUI 2.96
- 52 Week Low
- MAC $12.48
- ICUI $109.01
- 52 Week High
- MAC $22.27
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- MAC 50.20
- ICUI 31.29
- Support Level
- MAC $15.94
- ICUI $125.07
- Resistance Level
- MAC $17.30
- ICUI $130.57
- Average True Range (ATR)
- MAC 0.57
- ICUI 4.77
- MACD
- MAC -0.07
- ICUI -0.61
- Stochastic Oscillator
- MAC 38.89
- ICUI 15.38
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.1 million square feet of gross leasable area and averaged $837 sales per square foot over the 12 months ended in March 2025.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.